Description
Hyrimoz (adalimumab-adaz) is a biosimilar to Humira (adalimumab), a tumor necrosis factor (TNF) inhibitor indicated for the treatment of multiple chronic inflammatory conditions. It is approved for use in rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult and pediatric Crohn’s disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa. Hyrimoz exerts its therapeutic effect by binding to TNF-a, a pro-inflammatory cytokine, thereby blocking its interaction with TNF receptors and reducing inflammation and tissue destruction associated with autoimmune diseases.
Directions
Hyrimoz is administered via subcutaneous injection. Dosing varies depending on the indication, age, and patient-specific factors. For example:
- Rheumatoid arthritis: 40 mg every other week
- Crohn’s disease (adult): Initial dose of 160 mg, followed by 80 mg at week 2, then 40 mg every other week
- Plaque psoriasis: Initial dose of 80 mg, followed by 40 mg every other week starting one week later
Patients may self-administer Hyrimoz after appropriate training. The prefilled syringe or autoinjector should be stored in a refrigerator and allowed to reach room temperature before use. Injection sites should be rotated to avoid skin irritation.
Ingredients
Each 0.8 mL of Hyrimoz contains:
The formulation is preservative-free and latex-free.
Contraindications
Hyrimoz is contraindicated in patients with:
- Known hypersensitivity to adalimumab or any component of the formulation
- Active tuberculosis or other severe infections such as sepsis and opportunistic infections
- Moderate to severe heart failure (particularly NYHA class III/IV, in some indications)
Cautions
Before initiating therapy, patients should be evaluated for latent or active tuberculosis, and appropriate treatment should be started if needed. During treatment, patients should be monitored for signs of infection, malignancies, demyelinating disorders, and cytopenias. Live vaccines should be avoided during treatment. Use with other biologic immunomodulators (e.g., anakinra or abatacept) is not recommended due to increased risk of infection. Periodic monitoring of complete blood count, liver enzymes, and hepatitis B virus status is recommended.
Side Effects
Common side effects of Hyrimoz include:
- Injection site reactions (pain, erythema, pruritus)
- Upper respiratory infections
Serious adverse effects may include:
- Serious infections (e.g., tuberculosis, fungal, bacterial)
- Malignancies (e.g., lymphoma, skin cancer)
- Heart failure exacerbation
IMPORTANT NOTE:
The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.
Product Code : 14374